10） Narouze S, Benzon HT, Provenzano D, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant med-書．https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/630004_333900 3F1024_1_18（accessed Dec, 2020） 3） 医薬品医療機器総合機構．エリキュース錠添付文書．https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/670605_333900 4F1029_1_13（accessed Dec, 2020） 4） 医薬品医療機器総合機構．リクシアナ錠添付文書．https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/430574_333900 2F1020_1_12（accessed Dec, 2020） 5） Raval AN, Cigarroa JE, Chung MK, et al. Man-agement of patients on non-vitamin K antago-nist oral anticoagulants in the acute care and periprocedural setting：a scientific statement from the American Heart Association. Circula-tion 2017；135：e604—33. 6） Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association prac- tical guide on the use of non-vitamin K antago-nist oral anticoagulants in patients with atrial fibrillation. Euro Heart J 2018；39：1330—93. 7） Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or proce-dure. Substudy of the RE-LY trial. Thromb Hae-most 2015；113：625—32. 8） Qamar A, Vaduganathan M, Greenberger NJ, et al. Oral anticoagulation in patients with liver disease. Am Coll Cardiol 2018；71：2162—75. 9） Chen A, Stecker E, Warden BA. Direct oral anti-coagulant use：a practical guide to common clinical challenges. J Am Heart Assoc 2020；9：e017559.ications（second edition）：guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Region- al Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Insti-tute of Pain. Reg Anesth Pain Med 2018；43：225—62. 11） Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants：guidance from the anticoagulation forum. Am J Hematol 2019；94：697—709. 12） Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by haemodi-alysis. A phase Ⅰ single-centre study in patients with end-stage renal disease. Thromb Haemost 2013；109：596—605. 13） Parasrampuria DA, Marbury T, Matsushima N, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 2015；113：719—27. 14） Wang X, Mondal S, Wang J, et al. Effect of acti-vated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014；14：147—54. 15） Leitch J, van Vlymen J. Managing the perioper-ative patient on direct oral anticoagulants. J Can Anesth 2017；64：656—72. 16） Kawabata M, Goya M, Maeda S, et al. A survey of direct oral anticoagulant cessation in general surgery and outcomes in patients with nonval-vular atrial fibrillation. Int Heart J 2020；61：905—12.（香取 信之）202
元のページ ../index.html#7